Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune response.

数据证明了单次和重复剂量的INB-200，DeltEx抗药性免疫疗法（DRI）γ-δT细胞疗法诱导T细胞持久性和持续免疫应答的能力。

A treated patient, with paired tissue biopsies, demonstrated infiltration of gamma-delta T cells 148 days following a single administration in Cohort 1.

在组1中单次施用后148天，具有配对组织活检的治疗患者表现出γ-δT细胞的浸润。

Updated patient, survival and enrollment data from the ongoing INB-200 study to be presented at the Society for Neuro-Oncology (SNO) Annual Meeting on November 17, 2023 from 7:30 PM – 9:30 PM PT (Abstract Number: CTIM-42).

来自正在进行的INB-200研究的更新患者，生存和登记数据将于2023年11月17日下午7:30至晚上9:30在神经肿瘤学会（SNO）年会上公布（摘要编号：CTIM-42）。

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme (GBM) in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting..

纽约，2023年11月6日（GLOBE NEWSWIRE）-IN8bio，Inc。（纳斯达克股票代码：INAB），一家领先的临床阶段生物制药公司，专注于创新的γ-δT细胞疗法，今天在癌症免疫治疗学会（SITC）第38届年会的海报上展示了正在进行的INB-200针对新诊断的多形性胶质母细胞瘤（GBM）的1期临床试验的新生物相关数据。。

Chemotherapy has remained a mainstay of solid tumor treatment. Alkylating agents such as temozolomide (TMZ) can directly kill chemotherapy-sensitive GBM cells but can also sensitize chemotherapy resistant tumor cells to immune recognition by upregulating stress-associated NKG2D ligands (NKG2DL) to drive immunogenicity.

化疗仍然是实体瘤治疗的主流。烷化剂如替莫唑胺（TMZ）可以直接杀死化疗敏感的GBM细胞，但也可以通过上调应激相关的NKG2D配体（NKG2DL）来驱动免疫原性，从而使化疗耐药的肿瘤细胞对免疫识别敏感。

Unfortunately, the lymphodepleting effects of chemotherapy, such as TMZ, also kills T cells, and prevents an effective immune response to these stress targets. IN8bio’s DeltEx DRI gamma-delta T cells are designed to be resistant to chemotherapy, allowing them to remain functional and be used in combinations to create a strong synergistic tumor cell killing impact..

不幸的是，化疗的淋巴清除作用，如TMZ，也会杀死T细胞，并阻止对这些压力目标的有效免疫反应。IN8bio的DeltEx DRI gamma delta T细胞被设计为对化学疗法具有抗性，使其保持功能并组合使用以产生强烈的协同肿瘤细胞杀伤作用。。

“Gamma-delta T cells are important in immune responses and their high levels are known to correlate with improved survival outcomes. Efficient immune reconstitution is pivotal for favorable outcomes in cancer patients. This new analysis sheds light on how our DeltEx DRI gamma-delta T cell approach may induce durable persistence and immune responses,” said William Ho, Co-founder and CEO.

“Gamma delta T细胞在免疫反应中很重要，已知它们的高水平与改善的生存结果相关。有效的免疫重建对于癌症患者的有利结果至关重要。这一新分析揭示了我们的DeltEx DRI Gamma delta T细胞方法可能会诱导持久的持久性和免疫反应，“共同创始人兼首席执行官William Ho说。

“These important insights will help inform the ongoing development of our DeltEx DRI therapies across a variety of solid and hematological tumors..

“这些重要的见解将有助于为我们的DeltEx DRI疗法在各种实体和血液肿瘤中的持续发展提供信息。。

These data demonstrate that the lymphodepleting effects of chemotherapy results in a globally suppressed immune system where the DeltEx DRI gamma-delta T cells can strengthen the immune response and potentially broadly eliminate cancer cells. Furthermore, conventional standard-of-care can act as a long-term lymphodepleting agent, an important component for the development of allogeneic and potentially ‘off-the-shelf’ cellular therapies.

这些数据表明化疗的淋巴清除作用导致全球抑制的免疫系统，其中DeltEx DRI-γ-δT细胞可以增强免疫应答并可能广泛地消除癌细胞。此外，传统的护理标准可以作为长期淋巴消耗剂，这是开发同种异体和潜在“现成”细胞疗法的重要组成部分。

In June 2023, IN8bio presented positive data from the Phase 1 study of INB-200 in an oral presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. The Company will present updated patient, survival and enrollment data from the study at the Society for Neuro-Oncology (SNO) Annual Meeting taking place November 15-19, 2023..

2023年6月，IN8bio在美国临床肿瘤学会（ASCO）2023年会的口头报告中提供了INB-200第一阶段研究的积极数据。该公司将在2023年11月15日至19日举行的神经肿瘤学会（SNO）年会上提供该研究的最新患者，生存和登记数据。。

About INB-200

关于INB-200

INB-200 is a genetically modified autologous drug resistant immunotherapy (DRI) product candidate for the treatment of solid tumors. This novel platform utilizes genetic engineering to generate chemotherapy resistant gamma delta T cells which can be administered concurrently with standard-of-care treatment in solid tumors.

INB-200是用于治疗实体瘤的基因修饰的自体抗药性免疫疗法（DRI）产品候选物。这个新平台利用基因工程产生化疗耐药的γ-δT细胞，可以与实体瘤的标准治疗同时进行。

This is a powerful, synergistic treatment approach enabling gamma-delta T cells to persist in the presence of chemotherapy, and maintain their natural ability to recognize, engage and kill cancer cells..

这是一种强大的协同治疗方法，使γ-δT细胞能够在化疗的情况下持续存在，并保持其识别，参与和杀死癌细胞的天然能力。。

INB-200 is the first genetically engineered gamma-delta T cell therapy to be administered to patients with solid tumors and our initial indication is in GBM.

INB-200是第一个用于实体瘤患者的基因工程γ-δT细胞疗法，我们的初步适应症是GBM。

About IN8bio

大约在8Bio

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue.

IN8bio是一家临床阶段的生物制药公司，专注于固体和液体肿瘤的γ-δT细胞候选产品的发现，开发和商业化。γ-δT细胞是具有独特性质的特殊T细胞群，包括区分健康组织和患病组织的能力。

IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells..

IN8bio的DeltEx平台采用同种异体，自体，iPSC和转基因方法开发细胞疗法，旨在有效识别和根除肿瘤细胞。。

IN8bio has initiated a Phase 2 trial of INB-400 in glioblastoma (GBM) at multiple centers across the United States and has two ongoing Phase 1 trials in solid and hematological tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other hematological and solid tumor cancers.

IN8bio已在美国多个中心启动了INB-400在胶质母细胞瘤（GBM）中的2期临床试验，并正在进行两项实体和血液肿瘤的1期临床试验，包括用于GBM的INB-200和用于血液病患者的INB-100恶性肿瘤正在接受移植。IN8bio还拥有广泛的临床前计划组合，专注于解决其他血液和实体肿瘤癌症。

For more information about IN8bio and its programs, please visit www.IN8bio.com..

有关IN8bio及其程序的更多信息，请访问www.IN8bio.com。。

Forward Looking Statements

前瞻性声明

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words.

本新闻稿可能包含根据1995年“私人证券诉讼改革法”的安全港条款作出的前瞻性陈述。这些陈述可以用诸如“目标”、“预期”、“相信”、“可以”、“估计”、“期望”、“预测”、“目标”、“意图”、“可以”、“计划”、“可能”、“潜力”、“寻求”、“意愿”等词语来识别，这些词语或类似词语的变体旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements in this press release include, but are not limited to, statements regarding the development and continued progress and success of our preclinical and clinical trials and programs and product candidates; the timing of initiation, progress (including as to enrollment) and scope of clinical trials, including for INB-100 and INB-400; the success of gamma delta T cells as a treatment option for patients with both solid and hematological cancers; IN8bio’s progress towards and achievement of its goal of “Cancer Zero”; and IN8bio’s ability to achieve anticipated milestones, including expected data readouts from its trials, enrollment of additional patients in its clinical trials, advancement of clinical development plans and to develop new preclinical programs.

本新闻稿中的前瞻性声明包括但不限于关于我们的临床前和临床试验以及计划和产品候选人的发展和持续进展以及成功的声明；包括INB-100和INB-400在内的启动时间，进展（包括入学）和临床试验范围；γ-δT细胞作为固体和血液癌症患者的治疗选择的成功；IN8bio在实现“癌症零”目标方面的进展；IN8bio能够实现预期的里程碑，包括试验的预期数据读数，临床试验中其他患者的入选，临床开发计划的推进以及开发新的临床前计划。

IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, .

IN8bio实际上可能无法实现这些前瞻性陈述中披露的计划，意图或期望，您不应过分依赖这些前瞻性陈述。由于各种因素，实际结果或事件可能与这些前瞻性声明中披露的计划，意图和期望有很大不同，包括：现场启动风险，临床试验开始，患者登记和随访。

Company Contact:

公司联系人：

IN8bio, Inc.

IN8bio公司。

Patrick McCall

帕特里克·麦考尔

+ 1 646.600.6GDT (6438)

+1 646.600.6GDT（6438）

info@IN8bio.com

info@IN8bio.com

Investors & Media Contact:

投资者和媒体联系：

Argot Partners

Argot合作伙伴

IN8bio@argotpartners.com

IN8bio@argotpartners.com